about
Unknown quantities: HIV, viral hepatitis, and sexually transmitted infections in community corrections.A cross-sectional survey of prevalence and correlates of suicidal ideation and suicide attempts among prisoners in New South Wales, Australia.Offending, custody and opioid substitution therapy treatment utilisation among opioid-dependent people in contact with the criminal justice system: comparison of Indigenous and non-Indigenous AustraliansMortality among older adults with opioid use disorders in the Veteran's Health Administration, 2000-2011The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study."Seek, test, treat and retain" for hepatitis C in the United States criminal justice system.Geographic variability in HIV and injection drug use in Ukraine: implications for integration and expansion of drug treatment and HIV care.Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysisA literature review of international implementation of opioid substitution treatment in prisons: equivalence of care?Editorial commentary: Hepatitis C virus testing and drug use in north america; is there more than meets the eye?Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review.Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study.A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence.Excess mortality among opioid-using patients treated with oral naltrexone in Australia.Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: a 15-year observational cohort study.Evaluating health outcomes of criminal justice populations using record linkage: the importance of aliases.Factors associated with violent victimisation among homeless adults in Sydney, Australia.Imprisonment of opioid-dependent people in New South Wales, Australia, 2000–2012: a retrospective linkage study.A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.Hepatitis C Prevention and Needle Exchange Programs in Rhode Island: ENCORE.Presence of hepatitis C virus in syringes confiscated in prisons in Australia.A cross-sectional study of susceptibility to vaccine-preventable diseases among prison entrants in New South Wales.Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration.The contributions of viral hepatitis and alcohol to liver-related deaths in opioid-dependent people.Increased access to opioid substitution treatment in prisons is needed to ensure equivalence of care.Engagement with the criminal justice system among opioid-dependent people: a retrospective cohort study.Causes of death in a cohort treated for opioid dependence between 1985 and 2005.A comparative study of opioid substitution therapy utilisation among opioid-dependent men and women.To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?Inadequate data collection prevents health planning for released prisoners.An exploratory study of needlestick injuries among Australian prison officers.The ethics of hepatitis C "treatment as prevention" among prisoners.An estimate of the number of inmate separations from Australian prisons 2000/01 and 2005/06.Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings.Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) StudyReplyGlobal statistics on alcohol, tobacco and illicit drug use: 2017 status reportCompulsory detoxification is a major challenge to harm reduction in ChinaGlobal opioid agonist treatment: A review of clinical practices by countryPerceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
P50
Q33647812-215CBDFA-BF3C-4DCB-827E-6B6BD5E7ADE0Q34120743-04313349-62BE-4987-9EF4-BCB578C8DCE4Q34207684-AFC3B8AB-9612-4B6B-9098-3FAF12E15A7AQ35027505-1A1CECC6-29C6-43B2-BDBA-0BCF73875E0CQ35115444-E0CDDF3C-0552-4DDA-BD93-50915F6701BDQ35174428-06E5B4A8-EE69-4ACE-A97B-A4B271EAD698Q35734945-B3235B60-EEE2-420A-8BD1-9274A85B4646Q37045826-95939249-2733-4D7E-A842-6E715410B064Q37381542-0A9D5FC3-3E3E-4ED2-89D3-05DFBEDE656CQ37604532-39D6B671-BC87-4694-8A3F-572077D8A84AQ37676264-C5B2E63D-39ED-4404-BF99-00F186B9F773Q37704453-6913BFC1-BFA4-4D02-8CBA-CDA516C2593DQ38168314-E4154415-9DF4-4D93-9D18-78D01A3EF76EQ38258810-A8626190-6A9B-40E1-AD39-216E53A5C508Q38416854-5F9F0BD0-8A8C-43F5-8A32-0C844731F33BQ38493486-A94F066F-8F86-4491-BA16-371CF2120B70Q39954351-AE5CEA4B-9A5B-4486-B212-452A8CE15290Q41072782-391F3C71-54B7-41AA-8165-8214DDDE5C32Q41681373-37745935-99ED-4F7F-B16C-CAE211665054Q42208935-E4D2D9E8-928B-4417-9334-4A0936DB0708Q42991378-26430F51-E965-455B-B641-91A188C064E4Q43408391-AAFA0A69-8301-420F-B3E2-965BDB69D7BFQ44330216-2FC27EE0-3374-4127-8BDD-C5AFE47EDFC1Q44337133-24BF1DE0-7AE4-437A-9CB9-9232404EA1E2Q44337929-4022461E-A7B5-4A65-B2CE-A72D90483D46Q44340732-B31A7F63-6035-47DA-BAE2-F9C837A1729BQ44340864-7E6627BF-2479-4A68-99AC-F1E17B8D27AAQ44344923-969D2AE8-7C59-4AC5-838F-95CEB6266EE4Q44349921-EB872530-227E-43E8-84C6-10769976A27AQ45366945-D1884109-407D-4EF8-8079-9D571A39AA54Q47402325-C1DD76A1-EFF8-454C-9879-B4D477A6308AQ48077443-9AF4115C-6FE1-4080-8F2E-88B7C5A0C72CQ51148068-ED398948-A144-48E0-8F52-9DF5902AADCFQ51846147-46442BE4-99FB-47B1-91BB-31724D405FADQ56888804-74E1454B-0AD4-431A-9B8D-ED000DC22D1BQ57047110-FB9EB00C-8F05-49B1-ACF2-2949F3330830Q57133133-A9CBBA01-3086-4EB7-A49A-8BBCE77AC08CQ59532111-504B252F-291C-4CD2-9C3A-C08C226EBA00Q91913875-DAE4A4FF-7BB3-4E60-BECC-8A714DEDD026Q92150595-64B3BEBB-C63A-43F1-B7C1-4B54F02CB841
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sarah Larney
@ast
Sarah Larney
@en
Sarah Larney
@es
Sarah Larney
@nl
Sarah Larney
@sl
type
label
Sarah Larney
@ast
Sarah Larney
@en
Sarah Larney
@es
Sarah Larney
@nl
Sarah Larney
@sl
altLabel
Larney S
@en
prefLabel
Sarah Larney
@ast
Sarah Larney
@en
Sarah Larney
@es
Sarah Larney
@nl
Sarah Larney
@sl
P106
P1153
23970802300
P21
P31
P496
0000-0002-5602-4963